MedPage Today -- DURHAM, N.C., March 12 -- An investigational oral thrombin receptor antagonist didn’t increase bleeding in patients undergoing percutaneous coronary intervention (PCI), researchers here said.
MedPage Today -- DURHAM, N.C., March 12 -- An investigational oral thrombin receptor antagonist didn’t increase bleeding in patients undergoing percutaneous coronary intervention (PCI), researchers here said.